Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Baxter Pays $24 Million To Bring JV In-house

publication date: Jan 30, 2008

Baxter International will take its Shanghai Baxter JV completely in-house by buying the 40% stake in the JV that had been owned by Worldbest Treeful Pharmaceutical. Worldbest is in financial trouble, and the Bank of China ordered the JV stake to be put up for auction. Worldbest Treeful originally invested $4.8 million for a 40% participation in the venture. Baxter paid 180 million RMB, about $24.3 million, to acquire the position. More details...

Stock Symbol: (NYSE: BAX) 



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital